¼¼°èÀÇ Ç»¸° À¯»çü ¾à¹° ½ÃÀå º¸°í¼­(2025³â)
Purine Analogues Drugs Global Market Report 2025
»óǰÄÚµå : 1769725
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,310,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,121,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,932,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç»¸° À¯»çü ¾à¹° ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ³ëÀÎÃþÀÇ È®´ë, º¸´Ù À¯¸®ÇÑ ÇコÄÉ¾î »óȯÀÇ Æ² µîÀÌ ÀÖ½À´Ï´Ù.

Ç÷¾×ÇÐÀû ¾Ç¼º Á¾¾çÀÇ À¯º´·ü Áõ°¡´Â Ç»¸° À¯»çü ¾à¹° ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °í·ÉÀÚ¿¡¼­ À¯ÀüÀÚ º¯ÀÌÀÇ ÃàÀû°ú ¸é¿ª°èÀÇ È¿À² ÀúÇÏ¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. City of Hope´Â ¹Ì±¹¿¡¼­ ¾à 160¸¸ ¸íÀÌ ¹éÇ÷º´, °ñ¼öÁ¾, È£ÁöŲ ¸²ÇÁÁ¾, ºñÈ£ÁöŲ ¸²ÇÁÁ¾À» ¾Î°í ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

¶ÇÇÑ ÇコÄɾî ÁöÃâ Áõ°¡µµ Ç»¸° À¯»çü ¾à¹° ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ, Á¶Á÷¿¡ ÀÇÇÑ ÀçÁ¤ ÁöÃâÀÇ ÃѾ×ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ÁöÃâÀº ƯÈ÷ Àα¸ÀÇ °í·ÉÈ­¿Í ±×°Í¿¡ ¼ö¹ÝÇÏ´Â ¸¸¼º ÁúȯÀÇ ÀÌȯÀ² Áõ°¡¿¡ ÀÇÇØ Áõ°¡Çϰí ÀÖ¾î, Àå±âÀûÀÌ°í °í¾×ÀÇ Ä¡·á°¡ ÇÊ¿äÇÏ°Ô µÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡Çϸé Ç»¸° À¯»ç ¾à¹°ÀÇ ¿¬±¸, °³¹ß ¹× ¹èÆ÷°¡ ¿ëÀÌÇØÁ® ¾Ï ¹× ÀÚ°¡¸é¿ª Áúȯ°ú °°Àº Áúȯ¿¡ ´ëÇÑ °í±Þ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ º¸ÀåµË´Ï´Ù. ¿µ±¹ Åë°èû(Office for National Statistics)ÀÌ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é, 2023³âºÎÅÍ 2024³â±îÁö ÃÑ ÀÇ·áºñ ÁöÃâÀÌ ¸í¸ñ»ó 6.5% Áõ°¡ÇßÀ¸¸ç, ÀÌ´Â 2023³â¿¡ ±â·ÏµÈ 6.3% Áõ°¡À²º¸´Ù ¾à°£ ³ôÀº ¼öÄ¡ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Purine analogue drugs belong to a class of antimetabolite chemotherapy agents that structurally mimic purine nucleotides (adenine and guanine), which are crucial components of a cell's genetic material. These agents disrupt nucleic acid synthesis by imitating natural purines, thereby interfering with the replication and functionality of cancerous or fast-dividing cells.

The primary categories of drugs in the purine analogues class include cladribine, tioguanine, clofarabine, mercaptopurine, fludarabine, nelarabine, and others. Cladribine, for instance, is a chemotherapy agent that resembles purine nucleotides and is predominantly prescribed for treating hematologic cancers such as hairy cell leukemia and conditions like multiple sclerosis. These drugs are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by a wide range of end users, including hospitals, home care settings, specialty clinics, ambulatory surgical centers, and others.

The purine analogues drugs market research report is one of a series of new reports from The Business Research Company that provides purine analogues drugs market statistics, including purine analogues drugs industry global market size, regional shares, competitors with a purine analogues drugs market share, detailed purine analogues drugs market segments, market trends and opportunities, and any further data you may need to thrive in the purine analogues drugs industry. This purine analogues drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The purine analogues drugs market size has grown rapidly in recent years. It will grow from $14.77 billion in 2024 to $16.34 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The expansion during the historical period was supported by increased demand for targeted chemotherapy approaches, heightened research and development initiatives, greater utilization of combination therapy regimens, enhanced healthcare infrastructure in developing regions, and a rising number of patients with autoimmune conditions.

The purine analogues drugs market size is expected to see rapid growth in the next few years. It will grow to $24.69 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The projected growth is driven by heightened funding in drug discovery, broader implementation of personalized treatment strategies, increasing preference for orally administered purine analogues, expanding elderly demographic, and more favorable healthcare reimbursement frameworks. Key emerging trends include progress in targeted therapies, improvements in drug formulation methods, development of innovative combination treatments, adoption of digital health tools, and the evolution of biomarker-based therapeutic approaches.

The increasing prevalence of hematologic malignancies is anticipated to drive the growth of the purine analogues drugs market. Hematologic malignancies are cancers that originate in the body's blood-forming tissues, such as bone marrow, or in immune system cells. This rising prevalence is largely due to the aging population, as the likelihood of developing blood cancers like leukemia, lymphoma, and myeloma increases significantly with age. This is attributed to the accumulation of genetic mutations and a decline in immune system efficiency in older individuals. Purine analogue drugs are used to manage these malignancies by disrupting DNA synthesis in abnormal blood cells, thereby slowing or halting their uncontrolled growth. For example, in May 2024, the City of Hope, a US-based non-profit clinical research center, reported that approximately 1.6 million people in the United States are living with leukemia, myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Furthermore, over 192,000 new cases of blood cancer are projected to be diagnosed in 2025. As a result, the growing incidence of hematologic malignancies is contributing to the expansion of the purine analogues drugs market.

An increase in healthcare expenditure is also expected to support the growth of the purine analogues drugs market. Healthcare expenditure includes the total financial outlay by individuals, governments, and organizations on medical services, treatments, and infrastructure aimed at maintaining and improving public health. This expenditure is rising, particularly due to the aging population and the associated increase in chronic disease incidence, which necessitates long-term and often costly care. Greater healthcare spending facilitates the research, development, and distribution of purine analogue drugs, ensuring access to advanced therapies for conditions like cancer and autoimmune diseases. For instance, in April 2025, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure rose by 6.5% in nominal terms from 2023 to 2024, slightly higher than the 6.3% increase seen in 2023. Therefore, this rise in healthcare spending is contributing to the growth of the purine analogues drugs market.

In December 2022, Innovent Biologics Inc., a biotechnology company based in China, entered into a collaboration with LG Chem to launch a novel non-purine xanthine oxidase inhibitor (XOI) for the treatment of chronic gout and hyperuricemia. This partnership aims to support the development and commercialization of Tigulixostat in China, providing a new and safer therapeutic option for patients with gout and hyperuricemia. The collaboration leverages Innovent's local expertise and LG Chem's drug development capabilities. LG Chem, a chemical company based in South Korea, also offers a purine analog drug called allopurinol.

Major players in the purine analogues drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, GSK plc, Merck KGaA, Mylan N.V., Fresenius Kabi AG, Dr. Reddy's Laboratories Limited, Cipla Limited, Sagent Pharmaceuticals Incorporated, Taj Pharmaceuticals Limited, ScinoPharm Taiwan Limited, Zhejiang Cheng Yi Pharmaceutical Company Limited, Fermion Oy, Mac-Chem Products (India) Private Limited, Duchefa Farma B.V., Aetos Pharma Private Limited, Jigs Chemical Limited, Aark Pharmaceuticals, Aarti Pharmalabs Limited.

North America was the largest region in the purine analogues market in 2024. The regions covered in purine analogues drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the purine analogues drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The purine analogues drugs market consists of sales of tablets, oral solids, oral suspensions, intravenous (IV) solutions, lyophilized powder for injection, and ophthalmic ointment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Purine Analogues Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on purine analogues drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for purine analogues drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The purine analogues drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Purine Analogues Drugs Market Characteristics

3. Purine Analogues Drugs Market Trends And Strategies

4. Purine Analogues Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Purine Analogues Drugs Growth Analysis And Strategic Analysis Framework

6. Purine Analogues Drugs Market Segmentation

7. Purine Analogues Drugs Market Regional And Country Analysis

8. Asia-Pacific Purine Analogues Drugs Market

9. China Purine Analogues Drugs Market

10. India Purine Analogues Drugs Market

11. Japan Purine Analogues Drugs Market

12. Australia Purine Analogues Drugs Market

13. Indonesia Purine Analogues Drugs Market

14. South Korea Purine Analogues Drugs Market

15. Western Europe Purine Analogues Drugs Market

16. UK Purine Analogues Drugs Market

17. Germany Purine Analogues Drugs Market

18. France Purine Analogues Drugs Market

19. Italy Purine Analogues Drugs Market

20. Spain Purine Analogues Drugs Market

21. Eastern Europe Purine Analogues Drugs Market

22. Russia Purine Analogues Drugs Market

23. North America Purine Analogues Drugs Market

24. USA Purine Analogues Drugs Market

25. Canada Purine Analogues Drugs Market

26. South America Purine Analogues Drugs Market

27. Brazil Purine Analogues Drugs Market

28. Middle East Purine Analogues Drugs Market

29. Africa Purine Analogues Drugs Market

30. Purine Analogues Drugs Market Competitive Landscape And Company Profiles

31. Purine Analogues Drugs Market Other Major And Innovative Companies

32. Global Purine Analogues Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Purine Analogues Drugs Market

34. Recent Developments In The Purine Analogues Drugs Market

35. Purine Analogues Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â